Gonadal failure is associated with visceral adiposity in myotonic dystrophies

Elena Passeri, Enrico Bugiardini, Valeria A. Sansone, Alessandro Pizzocaro, Cinzia Fulceri, Rea Valaperta, Stefano Borgato, Elena Costa, Francesco Bandera, Bruno Ambrosi, Giovanni Meola, Luca Persani, Sabrina Corbetta

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Hypogonadism occurs in myotonic dystrophies type 1 (MD1) and type 2 (MD2). Sertoli and Leydig cell secretions, including insulin-like peptide-3 (INSL3), anti-Müllerian hormone (AMH) and inhibin B, were evaluated in male patients with MD. Design: Academic settings. Forty-four male patients with MD [31 MD1, 13 MD2, aged 59 (50-64) years, median (interquartile range)], age-, sex- and BMI-matched non-MD hypogonadal patients (n = 14) and healthy controls (n = 32). Serum FSH, LH, inhibin B, AMH, testosterone (T) and INSL3 were measured; fat and muscle masses were evaluated by DEXA. Results: Overt primary hypogonadism occurred in 29% of patients with MD1 and 46% of patients with MD2. Considering subclinical forms, the prevalence increased to 69% of MD1 and 100% of MD2. A half of patients with MD experienced symptoms. INSL3 levels were unaffected in most patients with MD. By contrast, AMH and inhibin B were reduced in most patients with MD and unrelated to age. Patients with MD showed increased body and visceral fat. Free T levels were negatively predicted by fat mass, and AMH and FSH levels were negatively correlated with waist/hip ratio and fat mass. AMH, inhibin B and FSH levels positively correlated with muscle strength and muscle mass. Conclusions: AMH and inhibin B secretion failures are common in male patients with MD and are more severe than Leydig cell hormones impairment. AMH and inhibin B measurements might provide clinical utility in evaluating fertility in patients with MD. Serum T, AMH and inhibin B productions are negatively influenced by increased fat mass, while AMH and inhibin B might be markers of muscle impairment.

Original languageEnglish
Pages (from-to)702-710
Number of pages9
JournalEuropean Journal of Clinical Investigation
Volume45
Issue number7
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Myotonic Dystrophy
Adiposity
Hormones
Fats
Muscle
Hypogonadism
Leydig Cells
Insulin
Peptides
Muscles
inhibin B
Waist-Hip Ratio
Intra-Abdominal Fat
Sertoli Cells
Muscle Strength
Serum
Testosterone
Fertility
Adipose Tissue

Keywords

  • Hypogonadism
  • Leydig cell
  • Myotonic dystrophies
  • Sertoli cell

ASJC Scopus subject areas

  • Medicine(all)
  • Clinical Biochemistry
  • Biochemistry

Cite this

Gonadal failure is associated with visceral adiposity in myotonic dystrophies. / Passeri, Elena; Bugiardini, Enrico; Sansone, Valeria A.; Pizzocaro, Alessandro; Fulceri, Cinzia; Valaperta, Rea; Borgato, Stefano; Costa, Elena; Bandera, Francesco; Ambrosi, Bruno; Meola, Giovanni; Persani, Luca; Corbetta, Sabrina.

In: European Journal of Clinical Investigation, Vol. 45, No. 7, 01.07.2015, p. 702-710.

Research output: Contribution to journalArticle

Passeri, Elena ; Bugiardini, Enrico ; Sansone, Valeria A. ; Pizzocaro, Alessandro ; Fulceri, Cinzia ; Valaperta, Rea ; Borgato, Stefano ; Costa, Elena ; Bandera, Francesco ; Ambrosi, Bruno ; Meola, Giovanni ; Persani, Luca ; Corbetta, Sabrina. / Gonadal failure is associated with visceral adiposity in myotonic dystrophies. In: European Journal of Clinical Investigation. 2015 ; Vol. 45, No. 7. pp. 702-710.
@article{7f70d97c10e84f53bfa9475e0cc2345b,
title = "Gonadal failure is associated with visceral adiposity in myotonic dystrophies",
abstract = "Background: Hypogonadism occurs in myotonic dystrophies type 1 (MD1) and type 2 (MD2). Sertoli and Leydig cell secretions, including insulin-like peptide-3 (INSL3), anti-M{\"u}llerian hormone (AMH) and inhibin B, were evaluated in male patients with MD. Design: Academic settings. Forty-four male patients with MD [31 MD1, 13 MD2, aged 59 (50-64) years, median (interquartile range)], age-, sex- and BMI-matched non-MD hypogonadal patients (n = 14) and healthy controls (n = 32). Serum FSH, LH, inhibin B, AMH, testosterone (T) and INSL3 were measured; fat and muscle masses were evaluated by DEXA. Results: Overt primary hypogonadism occurred in 29{\%} of patients with MD1 and 46{\%} of patients with MD2. Considering subclinical forms, the prevalence increased to 69{\%} of MD1 and 100{\%} of MD2. A half of patients with MD experienced symptoms. INSL3 levels were unaffected in most patients with MD. By contrast, AMH and inhibin B were reduced in most patients with MD and unrelated to age. Patients with MD showed increased body and visceral fat. Free T levels were negatively predicted by fat mass, and AMH and FSH levels were negatively correlated with waist/hip ratio and fat mass. AMH, inhibin B and FSH levels positively correlated with muscle strength and muscle mass. Conclusions: AMH and inhibin B secretion failures are common in male patients with MD and are more severe than Leydig cell hormones impairment. AMH and inhibin B measurements might provide clinical utility in evaluating fertility in patients with MD. Serum T, AMH and inhibin B productions are negatively influenced by increased fat mass, while AMH and inhibin B might be markers of muscle impairment.",
keywords = "Hypogonadism, Leydig cell, Myotonic dystrophies, Sertoli cell",
author = "Elena Passeri and Enrico Bugiardini and Sansone, {Valeria A.} and Alessandro Pizzocaro and Cinzia Fulceri and Rea Valaperta and Stefano Borgato and Elena Costa and Francesco Bandera and Bruno Ambrosi and Giovanni Meola and Luca Persani and Sabrina Corbetta",
year = "2015",
month = "7",
day = "1",
doi = "10.1111/eci.12459",
language = "English",
volume = "45",
pages = "702--710",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Blackwell Publishing Ltd",
number = "7",

}

TY - JOUR

T1 - Gonadal failure is associated with visceral adiposity in myotonic dystrophies

AU - Passeri, Elena

AU - Bugiardini, Enrico

AU - Sansone, Valeria A.

AU - Pizzocaro, Alessandro

AU - Fulceri, Cinzia

AU - Valaperta, Rea

AU - Borgato, Stefano

AU - Costa, Elena

AU - Bandera, Francesco

AU - Ambrosi, Bruno

AU - Meola, Giovanni

AU - Persani, Luca

AU - Corbetta, Sabrina

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background: Hypogonadism occurs in myotonic dystrophies type 1 (MD1) and type 2 (MD2). Sertoli and Leydig cell secretions, including insulin-like peptide-3 (INSL3), anti-Müllerian hormone (AMH) and inhibin B, were evaluated in male patients with MD. Design: Academic settings. Forty-four male patients with MD [31 MD1, 13 MD2, aged 59 (50-64) years, median (interquartile range)], age-, sex- and BMI-matched non-MD hypogonadal patients (n = 14) and healthy controls (n = 32). Serum FSH, LH, inhibin B, AMH, testosterone (T) and INSL3 were measured; fat and muscle masses were evaluated by DEXA. Results: Overt primary hypogonadism occurred in 29% of patients with MD1 and 46% of patients with MD2. Considering subclinical forms, the prevalence increased to 69% of MD1 and 100% of MD2. A half of patients with MD experienced symptoms. INSL3 levels were unaffected in most patients with MD. By contrast, AMH and inhibin B were reduced in most patients with MD and unrelated to age. Patients with MD showed increased body and visceral fat. Free T levels were negatively predicted by fat mass, and AMH and FSH levels were negatively correlated with waist/hip ratio and fat mass. AMH, inhibin B and FSH levels positively correlated with muscle strength and muscle mass. Conclusions: AMH and inhibin B secretion failures are common in male patients with MD and are more severe than Leydig cell hormones impairment. AMH and inhibin B measurements might provide clinical utility in evaluating fertility in patients with MD. Serum T, AMH and inhibin B productions are negatively influenced by increased fat mass, while AMH and inhibin B might be markers of muscle impairment.

AB - Background: Hypogonadism occurs in myotonic dystrophies type 1 (MD1) and type 2 (MD2). Sertoli and Leydig cell secretions, including insulin-like peptide-3 (INSL3), anti-Müllerian hormone (AMH) and inhibin B, were evaluated in male patients with MD. Design: Academic settings. Forty-four male patients with MD [31 MD1, 13 MD2, aged 59 (50-64) years, median (interquartile range)], age-, sex- and BMI-matched non-MD hypogonadal patients (n = 14) and healthy controls (n = 32). Serum FSH, LH, inhibin B, AMH, testosterone (T) and INSL3 were measured; fat and muscle masses were evaluated by DEXA. Results: Overt primary hypogonadism occurred in 29% of patients with MD1 and 46% of patients with MD2. Considering subclinical forms, the prevalence increased to 69% of MD1 and 100% of MD2. A half of patients with MD experienced symptoms. INSL3 levels were unaffected in most patients with MD. By contrast, AMH and inhibin B were reduced in most patients with MD and unrelated to age. Patients with MD showed increased body and visceral fat. Free T levels were negatively predicted by fat mass, and AMH and FSH levels were negatively correlated with waist/hip ratio and fat mass. AMH, inhibin B and FSH levels positively correlated with muscle strength and muscle mass. Conclusions: AMH and inhibin B secretion failures are common in male patients with MD and are more severe than Leydig cell hormones impairment. AMH and inhibin B measurements might provide clinical utility in evaluating fertility in patients with MD. Serum T, AMH and inhibin B productions are negatively influenced by increased fat mass, while AMH and inhibin B might be markers of muscle impairment.

KW - Hypogonadism

KW - Leydig cell

KW - Myotonic dystrophies

KW - Sertoli cell

UR - http://www.scopus.com/inward/record.url?scp=84933278851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933278851&partnerID=8YFLogxK

U2 - 10.1111/eci.12459

DO - 10.1111/eci.12459

M3 - Article

VL - 45

SP - 702

EP - 710

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 7

ER -